Cover Image
市場調查報告書

疫苗的製造技術與相關服務:全球市場分析

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

出版商 Visiongain Ltd 商品編碼 224393
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疫苗的製造技術與相關服務:全球市場分析 Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024
出版日期: 2014年03月11日 內容資訊: 英文 205 Pages
簡介

預測2014年全球的疫苗製造市場收益將達到7億562萬美元。在2014-2024年間更預測會有強勢成長。

本報告是針對全球的疫苗製造技術與相關服務的市場分析,包含疫苗ソ種類、可預防的疾病、疫苗製造的技術動向、以及最新的市場動向。並包含疫苗製造的外包市場預測,整體市場的SWOT分析、主要相關企業資料等,概述如下:

第1章 導論

第2章 疫苗市場概說

  • 疫苗為何?
  • 疫苗的歷史
  • 疫苗承包生產市場
    • 藥品、生物技術產業的外包
    • 外包的理由
    • 外包的優勢
    • 疫苗製造外包的問題
    • 疫苗製造必須要外包的理由是?
    • 戰略外包vs.戰術外包
    • 虛擬企業
    • 承包製造企業(CMO)
    • CMO可以提供的服務
    • 常見外包疫苗製造

第3章 疫苗製造技術

  • 疫苗技術動向摘要
  • 疫苗製造所需要的物質
    • 以細胞為主的製造技術
    • 以細胞為主的製造技術的優勢
    • 哺乳動物細胞系
    • 鳥類來源的細胞系
    • 來自植物的疫苗
    • 蟲卵為基礎的製造系統
  • 新型態技術可使得產量增加
    • AdVac技術:Crucell
    • AdCEV:AfriVax
    • Pfenex發現技術:Pfenex
  • 器材的趨勢
    • 單次使用的器材
    • 生物反應與疫苗
  • 預裝藥物注射器與疫苗
    • 預裝藥物注射器市場成長
    • 主要預裝藥物注射器疫苗產品
    • 預裝藥物注射器的催生因素及妨礙因素
    • 產品的穩定性和質量保證計劃
  • 疫苗的生產和冷凍乾燥
  • 細胞培養基可增加病毒的產生量

第4章 全球疫苗製造市場

  • 全球疫苗市場
  • 全球疫苗市場:2次市場區分
  • 孩童疫苗市場予測
  • 成人預防疫苗市場予測
  • 流感疫苗市場予測
  • 治療用疫苗市場予測

第5章 全球疫苗承包製造市場

  • 全球疫苗承包製造
  • 疫苗承包製造市場予測
  • 疫苗承包製造的主要國家與市場
  • 美國
  • 日本
  • EU 5國
  • 巴西
  • 俄羅斯
  • 印度
  • 中國

第6章 疫苗承包製造的主要企業

  • 疫苗承包製造市場仍然有併吞的可能性
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika GmbH
  • Lonza
  • Meridian Life Science
  • Sigma-Aldrich
  • SynCo Bio Partners
  • OSO BioPharmaceuticals Manufacturing
  • 主要疫苗承包製造企業(CMO)

第7章 SWOT分析

  • 疫苗承包製造產業分析
  • 優勢
  • 劣勢
  • 機會
  • 威脅

第8章 專門人士的見解

第9章 結論

  • 概要
  • 規格與高品質標準造成新公司加入困難
  • 治療用疫苗的豐富性
  • 新興市場的快速成長
  • 製造與技術催生因素的變化化

圖表表單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Vaccine manufacturing technology and services - your guide to trends and revenue prospects for vaccine production

What's the outlook for producing vaccines? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 205 page report provides 104 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2014 to 2024, with growing revenues.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of four exclusive expert opinion interviews from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:

  • Dr. Eluemuno Blyden, CEO and Founder, AfriVax
  • Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
  • Dr. Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
  • Dr. Stefan Beyer, Managing Director, Vibalogics

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting for these five world-level vaccine submarkets to 2024:

  • Paediatric vaccines
  • Influenza vaccines
  • Adult prophylactic vaccines
  • Therapeutic vaccines
  • Contract vaccine manufacturing

Our investigation shows business research and analysis with individual revenue forecasts and discussions. Which vaccine submarket will generate the most revenues? How will the vaccine contract manufacturing market expand? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

What are the prospects for vaccine contract manufacturing in the leading regions and countries?

Events and progress worldwide will influence the market, especially outsourced vaccine manufacturing in emerging countries.

In our study you will find individual revenue forecasts to 2024 for 11 vaccine contract manufacturing national markets:

  • US
  • Japan
  • Germany
  • Italy
  • Spain
  • France
  • UK
  • Russia
  • China
  • India
  • Brazil
  • RoW

Many opportunities exist within the vaccines contract manufacturing market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading companies and potential for market growth

Overall world revenue for the vaccines contract manufacturing market will reach $705.62m in 2014, our study forecasts. We predict strong revenue growth from 2014 to 2024. Our research shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:

  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika GmbH
  • Lonza
  • Meridian Life Science
  • Sigma-Aldrich
  • SynCo Bio Partners
  • OSO BioPharmaceuticals Manufacturing

In general, a company profile gives you the following information:

  • Overview of the company
  • Discussion of a company's activities and outlook including descriptions of leading products
  • Recent financial results
  • Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures

What issues will affect the vaccine contract manufacturing market?

Our new report discusses issues and events affecting the vaccine contract manufacturing market. You will find discussions, including qualitative analyses:

  • Healthy pipeline of vaccine products
  • Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods
  • Pandemic preparedness
  • Pricing, regulation and government policy
  • Perception of risk in outsourcing vaccine manufacturing

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024: Prospects For Leading Players report helps you

In summary, our 205 page report gives you the following knowledge:

  • Revenues forecasts to 2024 for the overall world vaccine market and 5 submarkets - discover the industry's prospects, finding promising places for investments and revenues
  • Assessment of 10 leading companies, and others, discovering their activities and outlooks
  • Market forecasting to 2024 for 11 leading national vaccine contract manufacturing markets - USA, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India, China and RoW
  • View opinions from our survey, seeing 4 interviews with leading authorities
  • Investigation of competition and opportunities influencing sales
  • Discussion of what stimulates and restrains the vaccine contract manufacturing market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how our report could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the vaccines market and vaccine contract manufacturing market. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Overview
  • 1.2. Review of the Vaccine Manufacturing Technology and Services Market
  • 1.3. Aims, Scope and Format of Report
  • 1.4. Research and Analysis Methods

2. Introduction to the Vaccine Market

  • 2.1. What Are Vaccines?
  • 2.2. The History of the Vaccine Market
  • 2.3. The Vaccine Contract Manufacturing Market
    • 2.3.1. Outsourcing in the Pharmaceutical and Biotechnology Industry
    • 2.3.2. Reasons to Outsource
    • 2.3.3. Benefits of Outsourcing
    • 2.3.4. The Challenges in Outsourcing Vaccine Manufacturing
    • 2.3.5. Why Should Companies Outsource Vaccine Manufacturing?
    • 2.3.6. Strategic Outsourcing vs. Tactical Outsourcing
    • 2.3.7. Virtual Companies
    • 2.3.8. Contract Manufacturing Organisations (CMOs)
    • 2.3.9. Manufacturing Services Offered by CMOs
    • 2.3.10. Vaccine Manufacturing Activities Typically Outsourced

3. Vaccine Manufacturing Technologies 2014

  • 3.1. Summary of Vaccine Technology Trends
  • 3.2. New Substrates for Vaccine Production
    • 3.2.1. Shift Towards Cell-Based Manufacturing Technology
    • 3.2.2. Benefits of Cell-Based Techniques
    • 3.2.3. Mammalian Cell Lines
      • 3.2.3.1. MCDK (Madin Darby Canine Kidney Cells)
      • 3.2.3.2. Vero Cells
      • 3.2.3.3. PerC6 Cells
    • 3.2.4. Avian-Derived Cell Lines
      • 3.2.4.1. EB66 Stem Cell Technology: Vivalis
    • 3.2.5. Plant-Based Vaccines
      • 3.2.5.1. Medicago's Proficia VLP Vaccine Technology
    • 3.2.6. Insect Egg-Based Production Systems
      • 3.2.6.1. Novavax's Sf9/BV Technology
      • 3.2.6.2. Protein Sciences Corporation (PSC): First Egg-Free Influenza Vaccine
  • 3.3. Next-Generation Expression Systems and Vectors: Increasing Production Yield
    • 3.3.1. AdVac Technology: Crucell
    • 3.3.2. AdCEV Vectors: AfriVax
    • 3.3.3. Pfenex Expression Technology: Pfenex
  • 3.4. Equipment Trends
    • 3.4.1. The Shift Towards Disposable Single-use Equipment
    • 3.4.2. Bioreactors and Vaccine Production
      • 3.4.2.1. Single-Use Bioreactors
      • 3.4.2.2. Main Applications of Disposable Bioreactors
      • 3.4.2.3. Current Single-Use Bioreactor Systems on the Market
  • 3.5. Prefilled Syringes and Vaccines
    • 3.5.1. Growing Market for Pre-Filled Syringes
    • 3.5.2. Leading Pre-Filled Vaccine Products 2014
    • 3.5.3. Drivers and Restraints for Pre-filled Syringes
    • 3.5.4. Product Stability and Quality Assurance Programme
      • 3.5.4.1. Paediatric H1N1 Vaccine
      • 3.5.4.2. Reported Challenges with Some Flu Vaccine
      • 3.5.4.3. Novartis' Agriflu and Fluad Ban is Lifted
      • 3.5.4.4. Baxter Flu Vaccine and Side Effects
      • 3.5.4.5. Reported Shelf Life Issues of Some H1N1 Vaccine
  • 3.6. Lyophilisation and Vaccine Manufacturing
  • 3.7. Cell Media Can Improve Virus Yield

4. The Vaccine Market 2014-2024

  • 4.1. The Global Vaccine Market, 2014-2024
  • 4.2. The Global Vaccine Market By Submarket, 2012 and 2013
  • 4.3. The Global Vaccine Market by Submarket, 2014-2024
  • 4.4. The Paediatric Vaccine Submarket Forecast, 2014-2024
    • 4.4.1. Growth of Paediatrics Vaccines is Driven by Prevnar's Blockbuster Success
    • 4.4.2. Paediatric Vaccines: The Biggest Segment, but the Least Dynamic
    • 4.4.3. Paediatric Vaccine Pipeline
  • 4.5. The Adult Prophylactic Vaccine Submarket Forecast, 2014-2024
    • 4.5.1. Adult Vaccination: Low Uptake
    • 4.5.2. Gardasil Represented Nearly a Fifth of Segment Revenues in 2012
    • 4.5.3. Adult Prophylactic Vaccines: Extensive Pipeline, but Still Needs to Become More Widely Established
    • 4.5.4. Adult Prophylactic Vaccine Pipeline
  • 4.6. The Influenza Vaccine Submarket, 2014-2024
    • 4.6.1. Influenza: Growth is Driven by Seasonal Epidemics and Global Pandemics
    • 4.6.2. Significant Scope for Enlarging the Patient Population
    • 4.6.3. Influenza Market: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed
    • 4.6.4. Influenza Product Pipeline
  • 4.7. The Therapeutic Vaccine Submarket, 2014-2024
    • 4.7.1. Therapeutic Vaccines: the Holy Grail of Personalised Vaccines
    • 4.7.2. Therapeutic Vaccines: On the Cusp of an Explosion or Another Vaccine Hype?
      • 4.7.2.1. Underperformance: Provenge is the First and Only FDA Approved Cancer Vaccine
      • 4.7.2.3. Biovac ID Completes Phase III for Cancer Vaccine
    • 4.7.3. Anti-Allergy Vaccines Make Up Bulk of Segment in 2013
      • 4.7.3.1. Canada Gives Merck & Co. its First Approval for Grass Allergy Vaccine Tablet
      • 4.7.3.2. Therapeutic Vaccine Product Pipeline

5. The Global Vaccine Contract Manufacturing Market 2014-2024

  • 5.1. Global Vaccine Contract Manufacturing: A Tiny Fraction of The Total Vaccine Market
  • 5.2. The Vaccine Contract Manufacturing Market Forecast: High Growth Rates from 2014-2024
    • 5.2.1. Trends in the Vaccine Contract Manufacturing Forecast
  • 5.3. The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
    • 5.3.1. The Leading National Markets for Vaccine Contract Manufacturing: Largely Dictated by the Local Vaccine Market
    • 5.3.2. The Leading National Markets for Vaccine Contract Manufacturing, 2012 and 2013
    • 5.3.3. The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
  • 5.4. The US Vaccine Contract Manufacturing Market Forecast, 2014-2024
  • 5.5. The Japanese Vaccine Contract Manufacturing Market Forecast, 2014-2024
    • 5.5.1. CMO's in Japan
  • 5.6. The EU5 Vaccine Contract Manufacturing Market, 2012 and 2013
    • 5.6.1. The EU5 Vaccine Contract Manufacturing Market, 2014-2024
    • 5.6.2. The French Vaccine Contract Manufacturing Market, 2014-2024
    • 5.6.3. The German Vaccine Contract Manufacturing Market, 2014-2024
    • 5.6.4. The Italian Vaccine Contract Manufacturing Market, 2014-2024
    • 5.6.5. The Spanish Vaccine Contract Manufacturing Market, 2014-2024
    • 5.6.6. The UK Vaccine Contract Manufacturing Market, 2014-2024
  • 5.7. The Brazilian Vaccine Contract Manufacturing Market, 2014-2024
  • 5.8. The Russian Vaccine Contract Manufacturing Market, 2014-2024
  • 5.9. The Indian Vaccine Contract Manufacturing Market, 2014-2024
  • 5.10. The Chinese Vaccine Contract Manufacturing Market, 2014-2024
    • 5.10.1. Vaccine Manufacturing: Questioning China's Regulatory Standards

6. The Leading Vaccine Contract Manufacturing Companies 2014-2024

  • 6.1. The Vaccine Contract Manufacturing Market has Room for Consolidation
  • 6.2. Baxter BioPharma Solutions
    • 6.2.1. Business Capabilities
  • 6.3. Boehringer Ingelheim
    • 6.3.1. Recent Financial Performance
    • 6.3.2. Boehringer Ingelheim's Ben Venue Closure
    • 6.3.3. Manufacturing Deals 2011-2014
    • 6.3.4. Boehringer Ingelheim Implements Fully Disposable Biopharmaceutical Manufacturing
    • 6.3.5. Boehringer Ingelheim Expands Biopharmaceuticals in China
    • 6.3.6. Outlook
  • 6.4. Catalent
    • 6.4.1. Recent Financial Performance, 2008-2012
    • 6.4.2. Recent Financial Performance by Segment, 2008-2012
    • 6.4.3. Catalent Injectable Vaccines
    • 6.4.4. Catalent Adjusts its Services
    • 6.4.5. Future Strategies for Growth
    • 6.4.6. Regional Market Expansion
  • 6.5. Charles River Laboratories
    • 6.5.1. Recent Financial Performance, 2008-2012
    • 6.5.2. Recent Financial Performance, 3Q 2013
    • 6.5.3. Recent Financial Performance by Segment
    • 6.5.4. Vaccine Manufacturing Services
      • 6.5.4.1. Vaccine Manufacturing Expansion
    • 6.5.5. Future Outlook and Early Stage Restructuring
    • 6.5.6. Partnerships
      • 6.5.6.1. Partnership with AstraZeneca
      • 6.5.6.2. Partnership with Batavia
  • 6.6. IDT Biologika GmbH
    • 6.6.1. Facility Expansion
    • 6.6.2. Acquisitions and Partnerships
      • 6.6.2.1. Acquisition of Riemser Pharma GmbH
      • 6.6.2.2. Partnership with ImVisioN Therapeutics
  • 6.7. Lonza
    • 6.7.1. Recent Financial Performance, 2010-2012
      • 6.7.1.1. Recent Financial Performance by Segment,2012
    • 6.7.2. Manufacturing Division Restructuring
  • 6.8. Meridian Life Science
    • 6.8.1. Recent Financial Performance, 2008-2013
      • 6.8.1.1. Recent Financial Performance by Segment, 2008-2013
      • 6.8.1.2. Recent Financial Performance by Region, 2012-2013
  • 6.9. Sigma-Aldrich
    • 6.9.1. Revenue and Recent Performance Analysis, 2010-2013
      • 6.9.1.1. Recent Financial Performance by Segment, 2010-2012
      • 6.9.1.2. Segment restructuring, 2013
    • 6.9.2. Strategy for Business Growth by Asian Expansion
    • 6.9.3. Acquisition of BioReliance
    • 6.9.4. Partnership with CatScl
  • 6.10. SynCo Bio Partners
    • 6.10.1. Recent Developments
      • 6.10.1.1. Expansion of Facilities
      • 6.10.1.2. FDA Approval of Partner Application
  • 6.11. OSO BioPharmaceuticals Manufacturing
    • 6.11.1. Facilities and Capabilities
    • 6.11.2. New Developments
      • 6.11.2.1. Acquisition of Catalent's Sterile Injectables Manufacturing Business
      • 6.11.2.2. Facility Investment
  • 6.12. Leading Vaccine Contract Manufacturing Organisations

7. SWOT Analysis of the Vaccine Contract Manufacturing Market 2014-2024

  • 7.1. Vaccine Contract Manufacturing Industry Trends
  • 7.2. Strengths
    • 7.2.1. Many Companies Cannot Afford In-house Capabilities
    • 7.2.2. Outsourcing Improves Time to Market
    • 7.2.3. Manufacturers get Access to Specialised Technologies
    • 7.2.4. Shift Towards Emerging Markets as Favourable Outsourcing Destinations
  • 7.3. Weaknesses
    • 7.3.1. Mass Vaccine Manufacturing is Kept In-house
    • 7.3.2. A Highly Fragmented Vaccine Contract Manufacturing Market
    • 7.3.3. An Unpredictable Supply and Demand Business Model
    • 7.3.4. Lack of Differentiation in the CMO Space
  • 7.4. Opportunities
    • 7.4.1. Many Vaccines in the Product Pipeline
    • 7.4.2. Therapeutic Vaccine Market could Explode
    • 7.4.3. Emerging Market's Growing Demand for Vaccines
      • 7.4.3.1. Dynamic Change: Emerging Markets are Major Vaccine Developers
  • 7.5. Threats
    • 7.5.1. Post Recession: Biotech Suffer from Severe Cuts in Capitalist Funding
    • 7.5.2. The Public are Slow to Accept Novel Technologies
    • 7.5.3. Perception of Risk by the Original Vaccine Manufacturers

8. Expert Opinion

  • 8.1. Interview with Dr. Eluemuno Blyden, CEO and Founder, AfriVax
    • 8.1.1. The Egg-based Vaccine Manufacturing Myth
    • 8.1.2. AfriVax's New Vaccine Manufacturing Technology
    • 8.1.3. Emerging Markets Pathing their Own Vaccine Path
  • 8.2. Interview with Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
    • 8.2.1. Growth of the Vaccine Contract Manufacturing Market
    • 8.2.2. The Therapeutic Vaccine Market
    • 8.2.3. The Use of Emerging Market Facilities
    • 8.2.4. The Vaccine Contract Manufacturing Business Model
  • 8.3. Interview with Dr Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
    • 8.3.1. Vaccine Contract Manufacturing Competition
    • 8.3.2. Target Diseases For Vaccine Development
    • 8.3.3. Challenge Stock Vaccines
    • 8.3.4. Meridian's Vaccine Contract Manufacturing Revenue Stream Breakdown
    • 8.3.5. The Changing Face of Large Pharma Drives Contract Manufacturing Growth
  • 8.4. Interview with Dr Stefan Beyer, Managing Director, Vibalogics
    • 8.4.1. The Benefits of Outsourcing Vaccine Manufacturing
    • 8.4.2. The Challenges in Manufacturing Vaccines

9. Conclusion

  • 9.1. Overview
  • 9.2. Regulatory and Quality Standards Create High Barriers of Entry
  • 9.3. Rich Pipeline for Therapeutic Vaccines
  • 9.4. Emerging Markets will Show Stronger Growth
  • 9.5. Technology Drives Changes in Manufacturing

List of Tables

  • Table 2.1: Timeline of Key Events in Vaccine Development, c.1000 AD - Present
  • Table 3.1: Vaccine Development Pipeline Using Protein Sciences Corporation's BEVS Vaccine Technology, 2014
  • Table 3.2: Vaccine Development Pipeline Using Crucell's AdVac Technology, 2014
  • Table 3.3: Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2014
  • Table 3.4: Companies Providing Disposable Biomanufacturing Platforms/Systems, 2014
  • Table 3.5: Some Leading Pre-Filled Syringe Vaccine Products, 2014
  • Table 3.6: Prominent Lyophilised Vaccines, 2014
  • Table 3.7: Examples of Serum-free Media for Vaccine Manufacturing, 2014
  • Table 4.1: The Global Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
  • Table 4.2: The Global Vaccine Market: Revenue ($bn), Market Share by Submarket (%), 2012-2013
  • Table 4.3: The Global Vaccine Market by Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
  • Table 4.4: The Paediatric Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
  • Table 4.5: Selected Pipeline Vaccines in Paediatric Submarket, 2014
  • Table 4.6: The Adult Prophylactic Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
  • Table 4.7: Selected Pipeline Vaccines in Adult Prophylactic Submarket, 2014
  • Table 4.8: The Influenza Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
  • Table 4.9: Selected Pipeline Vaccines in Influenza Submarket, 2014
  • Table 4.10: The Therapeutic Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
  • Table 4.11: Selected Pipeline Vaccines in Therapeutic Submarket, 2014
  • Table 5.1: The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.2: The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m), Market Share (%), 2012-2013
  • Table 5.3: The Leading National Vaccine Contract Manufacturing Markets Forecasts: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.4: The US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.5: The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.6: The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m), Market Share (%) by Country, 2012-2013
  • Table 5.7: The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.8: The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.9: The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.10: The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.11: The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.12: The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.13: The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.14: The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.15: The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 5.16: The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Table 6.1: Baxter BioPharma Solutions Capabilities, 2014
  • Table 6.2: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m), 2011-2012
  • Table 6.3: Catalent: Offerings and Services by Segment, 2014
  • Table 6.4: Catalent: Revenue($m), AGR (%), 2008-2012
  • Table 6.5: Catalent by Segment: Revenue($m), AGR (%), 2011-2012
  • Table 6.6: Charles River Laboratories: Services Provided by Segment, 2014
  • Table 6.7: Charles River Laboratories: Revenue ($bn), AGR (%), 2008-2012
  • Table 6.8: Charles River Laboratories: Pre-clinical Services Segment Revenue ($m), 3Q 2012-2013
  • Table 6.9: Charles River Laboratories: Revenue ($bn) by Segment, 2009-2012
  • Table 6.10: Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2014
  • Table 6.11: IDT: Work Units in the Vaccine Production Line
  • Table 6.12: Lonza Custom Manufacturing: Revenue ($bn), AGR (%), 2010-2012
  • Table 6.13: Lonza: Revenue ($bn), Market Share (%) by Segment, 2012
  • Table 6.14: Meridian Bioscience: Revenue ($m), AGR (%), 2008-2013
  • Table 6.15: Meridian Bioscience: Revenue ($m), AGR (%) by Segment, 2010-2013
  • Table 6.16: Meridian Life Science: Revenue ($m), AGR (%) by Region, 2012-2013
  • Table 6.17: Sigma Aldrich: Revenue ($bn), AGR (%), 2010-2012
  • Table 6.18: Sigma Aldrich: Revenue ($bn) by Segment, 2010-2012
  • Table 6.19: SynCo's Capabilities, 2014
  • Table 6.20: Leading Vaccine Contract Manufacturing Organisations, 2014
  • Table 7.1: SWOT Analysis of the Vaccine Contract Manufacturing Market, 2012-2024

List of Figures

  • Figure 2.1: Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry, 2014
  • Figure 3.1: Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2014
  • Figure 3.2: Medicago's Product Pipeline, 2014
  • Figure 3.3: Novavax' Insect Egg-Based Vaccine Production Process, 2014
  • Figure 3.4: Novavax's Product Pipeline, 2014
  • Figure 3.5: Single-Use Bioreactors Market, 2012
  • Figure 3.6: Pre-filled Syringes Market: Drivers and Restraints, 2014-2024
  • Figure 4.1: The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) 2012-2024
  • Figure 4.2: The Global Vaccine Market: Market Share by Submarket (%), 2013
  • Figure 4.3: The Paediatric Vaccine Market: Revenue ($bn), AGR (%), 2012-2024
  • Figure 4.4: The Adult Prophylactic Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
  • Figure 4.5: The Influenza Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
  • Figure 4.6: The Therapeutic Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
  • Figure 5.1: The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.2: The Leading National Vaccine Contract Manufacturing Markets: Revenue (%) by region, 2013
  • Figure 5.3: The US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Figure 5.4: The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Figure 5.5: The EU5 Vaccine Contract Manufacturing Markets: Revenue (%) by Country, 2013
  • Figure 5.6: The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.7: The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.8: The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.9: The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.10: The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.11: The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.12: The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.13: The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.14: The Indian Vaccines Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
  • Figure 5.15: The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
  • Figure 6.1: Boehringer Ingelheim: Typical Contract Manufacturing Process, 2014
  • Figure 6.2: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m), 2011-2012
  • Figure 6.3: Catalent: Revenue ($m), AGR (%), 2008-2012
  • Figure 6.4: Catalent: Market Share (%) by Segment, 2012
  • Figure 6.5: Charles River Laboratories: Revenue ($bn), AGR (%), 2008-2012
  • Figure 6.6: Charles River Laboratories: Revenue ($bn), AGR (%), 3Q 2012-2013
  • Figure 6.7: Charles River Laboratories: Market Share (%) by Segment, 2012
  • Figure 6.8: Lonza Custom Manufacturing: Revenue ($bn), AGR (%), 2010-2012
  • Figure 6.9: Lonza: Market Share (%) by Segment, 2012
  • Figure 6.10: Meridian Bioscience: Revenue ($m), AGR (%), 2008-2013
  • Figure 6.11: Meridian Bioscience: Revenue ($m) by Segment, 2010-2013
  • Figure 6.12: Meridian Bioscience: Market Share (%) by Segment,2013
  • Figure 6.13: Meridian Life Science: Market Share by Region, 2013
  • Figure 6.14: Sigma Aldrich: Revenue ($bn), AGR (%), 2010-2013
  • Figure 6.15: Sigma Aldrich: Market Share (%) by Segment, 2012
  • Figure 6.16: Sigma Aldrich: Market Share (%) by Segment, 2013
  • Figure 7.1: Vaccines in the Pipeline, Phase 1-3
  • Figure 7.2: Drivers and Restraints for the Vaccine Contract Manufacturing Sector, 2014-2024
  • Figure 9.1: Vaccine & Vaccine Contract Manufacturing Market: AGR(%), 2012-2024
  • Figure 9.2: Therapeutic Vaccines in the Pipeline, Phase 1-3

Companies Listed

  • AAI Pharma Services Corp.
  • AbbVie
  • Accugenix
  • Activaris Biotech
  • Adamis Pharmaceuticals
  • Aduro Biotech
  • Advanced Bioscience Laboratories, Inc.
  • Advaxis
  • AFFiRis
  • Afrivax
  • Agenus
  • ALK- Abello
  • Alpha Biologics
  • AlphaVax
  • Althea Technologies, Inc.
  • Ambiopharm
  • Amgen
  • AmProtein
  • Antigen Express
  • Antigenics
  • Aptuit CTS
  • Argos Therapeutics
  • Artelis
  • AstraZeneca
  • ATMI
  • ATMI LifeSciences
  • AuRx
  • Avista Capital Partners
  • Batavia
  • Bavarian Nordic
  • Baxter
  • Baxter BioPharma Solutions
  • Bayer
  • Bayer Healthcare
  • Bayhill Therapeutics
  • Beijing Tiantan Biological Products
  • Bellicum Pharmaceuticals
  • Ben Venue Laboratories
  • Bend Research
  • Berna Biotech
  • Bharat Biotech International
  • Binnopharm
  • Biofabri
  • BioKangtai
  • Biological E. Serum Institute
  • Biomay
  • Biondvax
  • Bionor Pharma
  • BioReliance
  • BioSante Pharmaceuticals
  • Biovest International
  • Biovian
  • BN ImmunoTherapeutics
  • Boehringer Ingelheim
  • Bosch
  • Cadila Pharmceuticals
  • Cancer Advances
  • Cardinal Health
  • Catalent
  • Catalent (Shanghai) Clinical Trial Supplies
  • Catalent Pharma Solutions
  • CatScl
  • Celldex Therapeutics
  • Cellexus Limited
  • CEL-SCI
  • Celtic Pharma
  • Cerebricon
  • CG Therapeutics
  • Charles River Biopharmaceutical Services
  • Charles River Laboratories
  • Chengdu Institute of Biological Products
  • China National Biotech Corporation
  • Chiron B.V
  • Circassia
  • CMC Biologics
  • Cobra Biologics
  • Colby Pharmaceutical
  • Cook Pharmica
  • Corden Pharma
  • Covance
  • Crucell
  • CSL Biologicals
  • Cytos Biotechnology
  • Cytovance Biologics
  • Daiichi Sankyo
  • Dalian Hissen Bio-Pharm
  • DBV Technologies
  • Dendreon
  • DSM Biologics
  • Dynport Vaccine
  • EMD Serono
  • Emergent BioSolutions
  • Endocyte
  • Etubics
  • Eurogentec Biologics
  • FiberCell
  • Frazier Healthcare
  • Fujifilm Diosynth Biotechnologies
  • Galena
  • Gcon
  • GE Healthcare Life Sciences
  • GE Wave Biotech
  • GeneCure Biotechnologies
  • Genetic Immunity
  • Genocea Biosciences
  • GenPhar
  • GenVec
  • GeoVax
  • GlaxoSmithKline Biologicals
  • Gliknik
  • Globelmmune
  • Goodwin Biotechnology Inc.
  • Gradalis
  • Grand River Aseptic Manufacturing
  • GSK
  • Hawaii Biotech
  • Heat Biologics
  • Hospira
  • HTD Biosystems
  • iBio
  • IDT Biologika GmbH
  • immatics biotechnologies
  • Immune Response Biopharma
  • Immune Targeting Systems
  • Immunitor
  • ImmunoCellular Therapeutics
  • ImmunoFrontier
  • Immunomic Therapeutics
  • Immunotope
  • Immunovaccine
  • Immunovative Therapies
  • ImmunsanT
  • ImVisioN Therapeutics
  • Innogenetics Biologicals
  • Inovio Pharmaceuticals
  • Intercell Corporation
  • Inviragen
  • Invitrogen
  • Irvine Scientific
  • Janssen Alzheimer Immunotherapy
  • Japan Vaccine Co
  • Jennerex
  • JHP Pharmaceuticals
  • JN-International Medical
  • Johnson & Johnson
  • Jubilant HollisterStier
  • Kuhner
  • Leidos
  • LG Life Sciences
  • LigoCyte Pharmaceuticals
  • Liquidia Technologies
  • Lonza
  • MabVax Therapeutics
  • Medicago
  • MedImmune
  • Meisser Filtration
  • Memgen
  • Merck
  • Merck Serono
  • Meridian Life Science
  • Millipore
  • Mitsubishi Tanabe Pharma
  • MorphoSys
  • MP Biomedicals
  • NanoBio
  • Nanotherapeutics
  • Nascent Biologics
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novadigm Therapeutics
  • Novartis
  • Novartis Vaccines and Diagnostics
  • NovaRX
  • Novasep
  • Novavax
  • OncoPep
  • Oncothyreon
  • Opal Therapeutics
  • Opexa Therapeutics
  • Optimer Biotechnology
  • Orban Biotech
  • Organon Teknika Corporation
  • OSO Biopharmaceuticals Manufacturing
  • Pall Life Sciences
  • Pantec
  • Paragon Bioservices
  • Patheon
  • PaxVax
  • PBS Biotech
  • Penn Pharma
  • Pfizer (Wyeth Pharmaceuticals)
  • Pfrenex
  • PharmAthene
  • Philip Morris International
  • Piedmont Research Center
  • Pierre-Guérin Biolafitte
  • Pique Therapeutics
  • Polynoma
  • Prima Biomed
  • ProBioGen
  • Profectus BioSciences
  • Protein Sciences Corporation
  • Rame-Hart Sanovo
  • Refine Technology
  • Riemser Pharma GmbH
  • Roche
  • SAFC
  • Sanaria
  • Sanofi Pasteur
  • Sanofi Pasteur MSD
  • Sartorius Stedim Biotech
  • Selecta Biosciences
  • Selecta RUS
  • Shanghai Sunway Biotech
  • ShangPharma Corporation
  • Shantha Biotech
  • Sigma Aldrich
  • Soligenix
  • Stallergenes
  • Stemline Therapeutics
  • Sumagen
  • Sunovion Pharmaceuticals
  • Synco Bio Partners
  • Takeda
  • TapImmune
  • TD Vaccines
  • Theraclone Sciences
  • Thermo Fisher scientific
  • Thymon
  • Transgene
  • TVAX Biomedical
  • United Biomedical
  • Vaccine Technologies
  • Vaccinogen
  • Vaxart
  • VaxInnate
  • VaxOnco
  • Vibalogics
  • Vivalis
  • Waisman Biomanufacturing
  • Wave Biotech
  • Xcellerex
  • Xencor
  • ZellWerk
  • Zhangjiang Biotech & Pharmaceutical Base
  • Zhejiang Jiang Yuan Tang Biotechnology Corporation

Other Organisations Mentioned in This Report

  • Aaron Diamond AIDS Research Center
  • Aeras Global TB Vaccine Foundation
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Centers for Disease Control and Prevention CDC (US)
  • Chinese State Food and Drug Administration (SFDA)
  • Defense Advanced Researched Projects Agency (DAPRA)
  • Emory University
  • European Medicines Agency (EMA)
  • Executive European Commission (European Union)
  • Health Canada
  • Hospital Clínic de Barcelona
  • Infectious Disease Research Institute (IDRI)
  • International AIDS Vaccine Initiative (IAVI)
  • Ministry of Industry and Trade (Russia)
  • Murdoch Childrens Research Institute
  • National Institute of Health (US)
  • PATH
  • Research Foundation for Microbial Diseases of Osaka University
  • The Department of Health and Human Services (HHS) (US)
  • The Drug Enforcement Administration (DEA) (US)
  • The Food and Drug Administration (FDA) (Korean)
  • The Food and Drug Administration (FDA) (US)
  • The National Institute of Allergy and Infectious Diseases (NIAID)
  • The U.S. Department of Health and Human Services Office of Biomedical Advanced Research and Development Authority (BARDA)
  • The United Nation Industrial Development Organisation (UNIDO)
  • US Naval Medical Research Center
  • Vaccine Manufacturers Associations (India)
  • World Health Organisation (WHO)
Back to Top